These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28295448)

  • 21. Drug-induced cholestasis.
    Bjornsson ES; Jonasson JG
    Clin Liver Dis; 2013 May; 17(2):191-209. PubMed ID: 23540497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An official ATS statement: hepatotoxicity of antituberculosis therapy.
    Saukkonen JJ; Cohn DL; Jasmer RM; Schenker S; Jereb JA; Nolan CM; Peloquin CA; Gordin FM; Nunes D; Strader DB; Bernardo J; Venkataramanan R; Sterling TR;
    Am J Respir Crit Care Med; 2006 Oct; 174(8):935-52. PubMed ID: 17021358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced liver injury.
    Leise MD; Poterucha JJ; Talwalkar JA
    Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results from a 2-year centralized tolcapone liver enzyme monitoring program.
    Lew MF; Kricorian G
    Clin Neuropharmacol; 2007; 30(5):281-6. PubMed ID: 17909306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The natural history of drug-induced liver injury.
    Björnsson E
    Semin Liver Dis; 2009 Nov; 29(4):357-63. PubMed ID: 19826969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury.
    Ozer JS; Chetty R; Kenna G; Palandra J; Zhang Y; Lanevschi A; Koppiker N; Souberbielle BE; Ramaiah SK
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):237-46. PubMed ID: 19903504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.
    Weil JG; Bains C; Linke A; Clark DW; Stirnadel HA; Hunt CM
    Regul Toxicol Pharmacol; 2008 Nov; 52(2):85-8. PubMed ID: 18585425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
    Powles T; Bracarda S; Chen M; Norry E; Compton N; Heise M; Hutson T; Harter P; Carpenter C; Pandite L; Kaplowitz N
    Eur J Cancer; 2015 Jul; 51(10):1293-302. PubMed ID: 25899987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute severe hepatitis with alemtuzumab and rechallenge after a year.
    Beattie W; Yan B; Sood S
    J Clin Neurosci; 2019 Feb; 60():158-160. PubMed ID: 30348589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
    Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
    Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury.
    Yano A; Oda S; Fukami T; Nakajima M; Yokoi T
    Toxicol Lett; 2014 Jul; 228(1):13-24. PubMed ID: 24747151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents.
    Devarbhavi H; Karanth D; Prasanna KS; Adarsh CK; Patil M
    Hepatology; 2011 Oct; 54(4):1344-50. PubMed ID: 21735470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase.
    Bailey WJ; Holder D; Patel H; Devlin P; Gonzalez RJ; Hamilton V; Muniappa N; Hamlin DM; Thomas CE; Sistare FD; Glaab WE
    Toxicol Sci; 2012 Dec; 130(2):229-44. PubMed ID: 22872058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-induced liver disease.
    Lewis JH; Ahmed M; Shobassy A; Palese C
    Curr Opin Gastroenterol; 2006 May; 22(3):223-33. PubMed ID: 16550036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins and elevated liver tests: what's the fuss?
    Onusko E
    J Fam Pract; 2008 Jul; 57(7):449-52. PubMed ID: 18625167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population.
    Makar GA; Weiner MG; Kimmel SE; Bennett D; Burke A; Yang YX; Han X; Sellers K; Nessel L; Lewis JD
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):43-51. PubMed ID: 17960855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-Induced Liver Disease: Clinical Course.
    Saithanyamurthi H; Faust AJ
    Clin Liver Dis; 2017 Feb; 21(1):21-34. PubMed ID: 27842773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pre-marketing ALT signal predicts post-marketing liver safety.
    Moylan CA; Suzuki A; Papay JI; Yuen NA; Ames M; Hunt CM
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):433-9. PubMed ID: 22668747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes.
    Hou FQ; Zeng Z; Wang GQ
    Cell Biochem Biophys; 2012 Nov; 64(2):77-83. PubMed ID: 22806342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.
    Lewis JH
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2173-89.e8. PubMed ID: 26116527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.